Stock · JUBLPHARMA · Healthcare
JUBLPHARMA share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for JUBILANT PHARMOVA LIMITED, refreshed every end-of-day run. A systematic, data-only read on JUBILANT PHARMOVA LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads JUBLPHARMA as constructive with a Crack Score of 71/100 as of 21 Jul 2026.
BazaarBaaziSource & method
The scanner's readScanned · scanned 21 Jul 2026
Where JUBLPHARMA stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
Scanned and scored this run, but the evidence is incomplete or conflicted. The engine fails closed to NO_TRADE.
Technical axis
84/100Fundamental axis
50/100Money flow
67/100Result pulse · Q4 FY26
60/100Technical evidence
Chaikin money flow +0.089 (accumulation)
up/down volume 1.32x (buyers dominant)
MFI 71.8
pocket pivot (institutional footprint)
relative strength rising vs NIFTY
RS slope +9.5% (3m)
outperforming and above 50DMA
Valuation and context
P/E 40.1 vs sector median 50.4 (0.8x, 36th pctile)
Red flags
above 200DMA (not a confirmed short-side trend)
Relative valuation
P/E (TTM)
40.1P/E vs sector
+0.8%Sector percentile
36PEG
n/aScanner levels from the deterministic engine run of 2026-07-21, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 21 Jul 2026
Support and resistance for JUBLPHARMA are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the JUBLPHARMA chart, refreshed every end-of-day run.
The Crack Score, and how it is built71 / 100 · Constructive
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for JUBLPHARMA, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on JUBLPHARMA reads right now.
The editorial price read on JUBLPHARMA is bullish. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on JUBLPHARMA can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving JUBLPHARMA.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 21 Jul 2026. Why JUBLPHARMA moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
JUBILANT PHARMOVA LIMITED's most recent quarter, parsed straight from the official NSE filing. Every figure links back to its primary source.
Result Pulse
60 / 100Revenue
Rs 2,290 crNet profit
Rs 119 crEPS (quarter)
Rs 7.55| Growth | YoY | QoQ |
|---|---|---|
| Revenue | +18.7% | +7.9% |
| Net profit | -21.1% | +113.8% |
| Net margin | +5.2% | |
Figures are the Q4 FY26 result for JUBILANT PHARMOVA LIMITED, parsed straight from the official NSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter32 quarters on record
JUBILANT PHARMOVA LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 30 Jun 2018. These are quarterly facts, not TTM valuation inputs.
JUBLPHARMA official result trail
32 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 2,290 cr | Rs 7.55 | n/a | n/a | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 2,123 cr | Rs 3.52 | n/a | 40/100 | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 1,966 cr | Rs 7.59 | n/a | 56/100 | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 1,901 cr | Rs 6.49 | n/a | 50/100 | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 1,929 cr | Rs 9.71 | n/a | 50/100 | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 1,822 cr | Rs 6.37 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 1,752 cr | Rs 6.47 | n/a | n/a | Filing |
| Q1 FY25ended 30 Jun 2024 / Consolidated, audited | Rs 1,732 cr | Rs 30.44 | n/a | n/a | Filing |
| Q4 FY24ended 31 Mar 2024 / Consolidated, audited | Rs 176 cr | Rs -3.69 | n/a | n/a | Filing |
| Q3 FY24ended 31 Dec 2023 / Consolidated, audited | Rs 1,677 cr | Rs 4.22 | n/a | n/a | Filing |
| Q2 FY24ended 30 Sep 2023 / Consolidated, audited | Rs 1,680 cr | Rs 3.94 | n/a | n/a | Filing |
| Q1 FY24ended 30 Jun 2023 / Consolidated, audited | Rs 1,587 cr | Rs 0.40 | n/a | n/a | Filing |
| Q4 FY23ended 31 Mar 2023 / Consolidated, audited | Rs 1,678 cr | Rs -6.15 | n/a | n/a | Filing |
| Q3 FY23ended 31 Dec 2022 / Consolidated, audited | Rs 1,553 cr | Rs -0.98 | n/a | n/a | Filing |
| Q2 FY23ended 30 Sep 2022 / Consolidated, audited | Rs 1,600 cr | Rs 0.34 | n/a | n/a | Filing |
| Q1 FY23ended 30 Jun 2022 / Consolidated, audited | Rs 1,440 cr | Rs 2.96 | n/a | n/a | Filing |
| Q4 FY22ended 31 Mar 2022 / Consolidated, audited | Rs 1,514 cr | Rs 3.74 | n/a | n/a | Filing |
| Q3 FY22ended 31 Dec 2021 / Consolidated, audited | Rs 1,311 cr | Rs 3.20 | n/a | n/a | Filing |
| Q2 FY22ended 30 Sep 2021 / Consolidated, audited | Rs 1,657 cr | Rs 8.97 | n/a | n/a | Filing |
| Q1 FY22ended 30 Jun 2021 / Consolidated, audited | Rs 1,635 cr | Rs 10.09 | n/a | n/a | Filing |
| Q4 FY21ended 31 Mar 2021 / Consolidated, audited | Rs 1,580 cr | Rs 13.43 | n/a | n/a | Filing |
| Q3 FY21ended 31 Dec 2020 / Consolidated, audited | Rs 1,771 cr | Rs 19.46 | n/a | n/a | Filing |
| Q2 FY21ended 30 Sep 2020 / Consolidated, audited | Rs 2,375 cr | Rs 14.06 | n/a | n/a | Filing |
| Q1 FY21ended 30 Jun 2020 / Consolidated, audited | Rs 1,893 cr | Rs 5.53 | n/a | n/a | Filing |
| Q4 FY20ended 31 Mar 2020 / Consolidated, audited | Rs 2,391 cr | Rs 16.35 | n/a | n/a | Filing |
| Q3 FY20ended 31 Dec 2019 / Consolidated, audited | Rs 2,315 cr | Rs 12.77 | n/a | n/a | Filing |
| Q2 FY20ended 30 Sep 2019 / Consolidated, audited | Rs 2,266 cr | Rs 15.66 | n/a | n/a | Filing |
| Q1 FY20ended 30 Jun 2019 / Consolidated, audited | Rs 2,182 cr | Rs 11.61 | n/a | n/a | Filing |
| Q4 FY19ended 31 Mar 2019 / Consolidated, audited | Rs 2,386 cr | Rs -6.38 | n/a | n/a | Filing |
| Q3 FY19ended 31 Dec 2018 / Consolidated, audited | Rs 2,377 cr | Rs 16.74 | n/a | n/a | Filing |
| Q2 FY19ended 30 Sep 2018 / Consolidated, audited | Rs 2,269 cr | Rs 13.50 | n/a | n/a | Filing |
| Q1 FY19ended 30 Jun 2018 / Consolidated, audited | Rs 2,079 cr | Rs 13.00 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
JUBILANT PHARMOVA LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
8,280 crNet profit (TTM)
398 crEBIT (TTM)
826 crProfit before tax (TTM)
614 crNet margin (TTM)
4.8%Finance costs (TTM)
212 crBalance sheet, as filed 2026-03-31
Total assets
15,523 crShareholder equity
7,096 crTotal borrowings
3,220 crCash and equivalents
1,267 crInventory
1,232 crTrade receivables
1,070 crThe cash engine, latest filed year
Operating cash flow
1,227 crCapex
1,449 crFree cash flow
-222 crInvesting flow
-1,260 crFinancing flow
94.9 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 8,280 cr | 398 cr | 7,096 cr | 3,220 cr | 1,227 cr |
| FY25 | 7,235 cr | 836 cr | 6,239 cr | 2,437 cr | 1,072 cr |
| FY24 | 670 cr | 7.3 cr | 542 cr | 341 cr | 97.1 cr |
| FY23 | 6,282 cr | -64.9 cr | 5,392 cr | 3,410 cr | 661 cr |
| FY22 | 6,059 cr | 413 cr | 5,316 cr | 2,928 cr | 838 cr |
| FY21 | 6,099 cr | 836 cr | 4,742 cr | 2,584 cr | n/a |
Every figure is parsed from JUBILANT PHARMOVA LIMITED's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
Management on record23 earnings calls
Every JUBLPHARMA earnings call BazaarBaazi has indexed, latest 31 May 2026. Read management in its own words, straight from the filed transcript.
JUBILANT PHARMOVA LIMITED earnings calls on record
23 calls since 31 Jan 2018
Show 15 older calls
Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.
What changed2 disclosures
Every recent official filing from JUBILANT PHARMOVA LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
JUBILANT PHARMOVA LIMITED has filed 2 official disclosures recently. The most recent is a Earnings dated 31 Mar 2026.
Event Heat
67 / 100Event Heat is a dated net read of JUBILANT PHARMOVA LIMITED's last 180 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the JUBLPHARMA chart. Not a substitute for a registered research note.
| Ticker | JUBLPHARMA |
|---|---|
| Full name | JUBILANT PHARMOVA LIMITED |
| Sector | Healthcare |
| Index class | MID CAP |
| ISIN | INE700A01033 |
| Market-cap band | ~15,925 cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 21 Jul 2026 |
| Aliases tracked | JUBLPHARMA |
Reference chartLevels in show
The daily frame the desk reads on JUBLPHARMA.
FAQ11 reader questions · AEO-eligible
The line on JUBLPHARMA, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the JUBLPHARMA share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on JUBLPHARMA. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.
What is BazaarBaazi's Crack Score for JUBLPHARMA?
The BazaarBaazi Crack Score for JUBLPHARMA is 71 out of 100 as of 21 Jul 2026, a constructive reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on JUBLPHARMA?
Strike-level option inventory for JUBLPHARMA is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is JUBLPHARMA in and which peers does BazaarBaazi track?
JUBLPHARMA sits in Healthcare (mid cap), indicative market cap ~15,925 cr (indicative), ISIN INE700A01033. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on JUBILANT PHARMOVA LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the JUBLPHARMA view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on JUBLPHARMA is bullish, published in Systematic Read on 21 Jul 2026.
Is JUBLPHARMA a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-21 run of the 500-name BazaarBaazi setup scanner, JUBILANT PHARMOVA LIMITED sits in the Scanned tier with a setup score of 67/100 (technical 84, fundamental 50). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
Where can I read JUBILANT PHARMOVA LIMITED's earnings call transcripts?
BazaarBaazi indexes 23 JUBLPHARMA earnings calls going back to 2018-01-31, latest 2026-05-31. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.
What was JUBILANT PHARMOVA LIMITED's Q4 FY26 net profit?
JUBILANT PHARMOVA LIMITED reported a net profit of Rs 119 cr for Q4 FY26 (the quarter ended 31 March 2026). That is -21.1% year on year. The figure is from the company's official NSE filing.
What was JUBILANT PHARMOVA LIMITED's Q4 FY26 revenue?
JUBILANT PHARMOVA LIMITED reported revenue of Rs 2,290 cr for Q4 FY26. That is +18.7% year on year. The figure is from the company's official NSE filing.
How does BazaarBaazi rate JUBILANT PHARMOVA LIMITED's Q4 FY26 result?
BazaarBaazi gives JUBILANT PHARMOVA LIMITED's Q4 FY26 result a Result Pulse of 60 out of 100, with a verdict of Steady. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Jubilant Pharmova Ltd announced recently?
The most recent official filing on record for Jubilant Pharmova Ltd is an earnings dated 31 Mar 2026. It is the company's own earnings disclosure to the exchange, and it links to that filing on the BazaarBaazi stock page rather than to any third-party summary.
Related stock views
The names BazaarBaazi reads alongside JUBLPHARMA, each a living view refreshed every end-of-day run.